CRISPRO · KNOWLEDGE BASE
Back to ResearchCrisPRO Blog
Insights, news, and research at the intersection of AI and oncology — organized by series where it matters.
Featured Article
EscapeMap — We Built a Cancer Resistance Engine From Public Data Nobody Was Using
A research series on building AI-driven therapeutic intelligence from the graveyard of failed clinical trials.
Read Full StoryMore articles
May 08, 2026
Building Brain Metastasis Framework Studying Glioblastoma's (GBM) Trial Failures
Every GBM trial failure carries a failure signature — a specific combination of target validity, delivery architecture, patient selection, and resistance mechanism. The question for each trial is not "did it fail?" but "which failure mode applies, and does that mode exist in the BrM context?"
April 19, 2026
Part 2 — NCT02264678 CAPRI: Ceralasertib + Olaparib and the BRCA resistance problem.
Trial: NCT02264678 (CAPRI) Drugs: Ceralasertib (ATRi) + Olaparib (PARPi) Cancer: Recurrent high-grade serous ovarian carcinoma (HGSOC) Published: Drew et al., JCO 2022 CrisPRO delta:+0.108
April 18, 2026
Part 1: Adavosertib — NCT03579316 (CrisPRO, WEE1, and PTEN Loss)
Trial: NCT03579316 Drug: Adavosertib (AZD1775) — WEE1 kinase inhibitor Combination: + Gemcitabine Cancer: Recurrent/refractory solid tumors (ovarian focus) Published: JCO 2023 — PMID referenced in CrisPRO validation run CrisPRO delta: +0.307 — strongest of all 5 validations
April 09, 2026
Part 2: Who is the system failing most, and why?
We built a computational engine and pointed it at 427 real ovarian cancer patients. We asked one question: who is the system failing most, and why?